9 Logistics And Distribution Recommendations For Cell And Gene Therapies

Cell and gene therapies are advancing rapidly toward commercialization, but their success depends heavily on carefully designed logistics and distribution strategies. This article outlines nine practical recommendations to help manufacturers prepare for the complexities of bringing these therapies to market. Key considerations include aligning distribution with where patients and key opinion leaders are located, assessing whether treatment sites can meet stringent storage requirements, and accounting for differences in how therapies are administered across care settings. Learn about the importance of planning reimbursement pathways early, coordinating cross-functional teams, and establishing clear operational processes before launch.

Manufacturers are encouraged to test end-to-end supply chains, anticipate disruptions, and incorporate buffer capacity into logistics planning. Packaging and labeling decisions must also be evaluated for their regulatory and operational impact. Finally, clear communication across clinical, regulatory, and supply chain stakeholders is essential to avoid misunderstandings and ensure timely delivery to patients.

Access the full article below to learn more.